Wednesday, 12 October 2016

Synairgen says AstraZeneca stops mid-stage asthma drug study

(Reuters) - Drug developer Synairgen Plc said its partner AstraZeneca Plc stopped a mid-stage study that was testing Synairgen's drug candidate as a potential treatment for severe asthma.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)